

In the Claims

1. (Original) A pharmaceutical composition comprising two or more therapeutic agents selected from the group consisting of:
 - (a) azo-bonded 4-APAA compound;
 - (b) non-azo bonded 4-APAA compound;
 - (c) azo-bonded 5-ASA compound;
 - (d) non-azo bonded 5-ASA compound;
 - (e) 4-APAA compound azo bonded to a 5-ASA compound.
2. (Original) The pharmaceutical composition of claim 1 further comprising a third therapeutic agent selected from the group consisting of: steroids, antibiotics,
3. (Original) The pharmaceutical composition of claim 1 formulated to deliver the therapeutic agents to the small intestine and/or the colon.
4. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the small intestine and the colon.
5. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the distal portion of the small intestine and the colon.
6. (Original) The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the colon.
7. (Original) The pharmaceutical composition of claim 1 formulated to pass through the stomach and to release the active agent in the intestine.
8. (Original) The pharmaceutical composition of claim 1 formulated as a suppository.
9. (Original) The pharmaceutical composition of claim 1 formulated for administration as an enema.
10. (Original) The pharmaceutical composition of claim 1 formulated as a mouth wash.

11. (Original) The pharmaceutical composition of claim 1 formulated for vaginal administration.
12. (Original) The pharmaceutical composition of claim 1 formulated for intra-uterine administration.
13. (Original) The pharmaceutical composition of claim 1 formulated for topical administration.
14. (Original) The pharmaceutical composition of claim 1 formulated for administration to the eye.
15. (Original) The pharmaceutical composition of claim 1 formulated to release:
 - (a) at least one component selected from:
 - (i) a first component comprising one or more of the therapeutic agents formulated for release in the stomach,
 - (ii) a second component comprising one or more of the therapeutic agents formulated for release in the small intestine or distal portion of the small intestine, and
 - (b) a third component comprising one or more of the therapeutic agents formulated for release in the colon.
16. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:
 - (a) the first component comprises a 5-ASA compound;
 - (b) the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
17. (Currently amended) The pharmaceutical composition of claim 15 θ -wherein:
 - (a) the first component comprises a 5-ASA compound;
 - (b) the second component comprises:
 - (i) a 5-ASA compound formulated for release in the small intestine;
 - (ii) a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
18. (Currently amended) The pharmaceutical composition of claim 15 θ -wherein:
 - (a) the first component comprises a 5-ASA compound;
 - (b) the second component is not present;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

19. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

(a) the first component comprises a 5-ASA compound;

(b) the second component comprises a 5-ASA compound formulated for release in the small intestine ;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

20. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

(a) the first component comprises a 4-APAA compound;

(b) the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

21. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

(a) the first component comprises a 4-APAA compound;

(b) the second component comprises:

(i) a 4-APAA compound formulated for release in the small intestine; and

(ii) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

22. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

(a) the first component comprises a 4-APAA compound;

(b) the second component is not present;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

23. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

(a) the first component comprises a 4-APAA compound;

(b) the second component comprises a 4-APAA compound formulated for release in the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

24. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

- (a) the first component is not present;
 - (b) the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
25. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:
- (a) the first component is not present;
 - (b) the second component comprises:
 - (i) a 5-ASA compound formulated for release in the small intestine;
 - (ii) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
26. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:
- (a) the first component is not present;
 - (b) the second component comprises a 5-ASA compound formulated for release in the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
27. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:
- (a) the first component is not present;
 - (b) the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
28. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:
- (a) the first component is not present;
 - (b) the second component comprises:
 - (i) a 4-APAA compound formulated for release in the small intestine; and
 - (b) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
 - (c) the third component comprises a 5-ASA compound and a 4-APAA compound.
29. (Currently amended) The pharmaceutical composition of claim 15 θ wherein:

- (a) the first component is not present;
- (b) the second component comprises a 4-APAA compound formulated for release in the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

30. (Previously presented) A method of treating an inflammatory gastrointestinal condition comprising administering to a subject a pharmaceutical composition of claim 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 in an amount sufficient to reduce the inflammatory gastrointestinal condition.

31. (Cancelled).